Altabax

Altabax is a brand name of retapamulin topical, approved by the FDA in the following formulation(s):

ALTABAX (retapamulin - ointment; topical)

• 
  Manufacturer: GLAXO GRP LTD
  
  Approval date: April 12, 2007
  
  Strength(s): 1% ^[RLD]

Has a generic version of Altabax been approved?

No. There is currently no therapeutically equivalent version of Altabax available.

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Altabax. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• 
  Process salts compositions and use
  Patent 7,875,630
  Issued: January 25, 2011
  Inventor(s): Breen; Gary Francis & Forth; Michael Anthony & Kopelman; Susan ShuMei Hu & Muller; Francis Xavier & Sanderson; Francis Dominic
  Assignee(s): Glaxo Group Limited
  The present invention provides a novel process for preparing pleuromutilin derivatives, novel salts of mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or solvates thereof, novel pharmaceutical compositions or formulations for topical administration comprising mutilin 14-(exo-8-methyl-8-azabicyclo[3.2.1]oct-3-ylsulfanyl)-acetate or a pharmaceutically acceptable salt or solvate thereof and their use in medical therapy, particularly antibacterial therapy.
  
  Patent expiration dates:
  
  
  • February 14, 2027
    
    ✓ 
    Drug substance
  
  



• 
  Pleuromutilin derivatives as antimicrobials
  Patent RE39128
  Issued: June 13, 2006
  Inventor(s): Berry; Valerie Joan & Dabbs; Steven & Frydrych; Colin Henry & Hunt; Eric & Sanderson; Francis Dominic & Woodnutt; Gary
  Assignee(s): SmithKline Beecham p.l.c.
  The present invention relates to pleuromutilin derivatives, to processes for their preparation, to pharmaceutical compositions containing them and to their use in medical therapy, particularly antibacterial therapy.
  
  Patent expiration dates:
  
  
  • April 12, 2021
    
    ✓ 
    Patent use: TREATMENT OF IMPETIGO DUE TO STAPHYLOCOCCUS AUREUS OR STREPTOCOCCUS PYOGENES
    ✓ 
    Drug substance
    ✓ 
    Drug product
  
  

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • April 12, 2012 - NEW CHEMICAL ENTITY
  
  

See also...

• Altabax Consumer Information (Drugs.com)
• Altabax Ointment Consumer Information (Wolters Kluwer)
• Altabax Consumer Information (Cerner Multum)
• Altabax Advanced Consumer Information (Micromedex)
• Altabax AHFS DI Monographs (ASHP)
• Retapamulin Ointment Consumer Information (Wolters Kluwer)
• Retapamulin topical Consumer Information (Cerner Multum)
• Retapamulin Topical application Advanced Consumer Information (Micromedex)
• Retapamulin AHFS DI Monographs (ASHP)